EUVIMEDEUVIMED entdecken
Crossref

IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function

Yaning Yang, Chengming Liu, Lu Yang, Sufei Zheng, Haiyan Xu, Shuyang Zhang, Linyan Tian, Nan Sun, Jie He, Yan Wang

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yaning Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Interleukin-6, Lung Neoplasms, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Beijing Xisike Clinical Oncology Research Foundation, Youth Science Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary resistance to first-line chemoimmunotherapy remains a significant challenge in treating advanced non-small cell lung cancer (NSCLC). Although cytokines such as interleukin-6 (IL-6) have been implicated in resistance to immune checkpoint inhibitor (ICI) monotherapy, their predictive value for chemoimmunotherapy outcomes and the underlying mechanisms are less defined. This study investigated the prognostic significance of the baseline plasma IL-6 levels and the role of this cytokine in shaping the tumour immune microenvironment (TIME) of NSCLC. Here, we retrospectively analysed data on 123 advanced NSCLC patients treated with anti-PD-1 inhibitors plus chemotherapy. Baseline plasma IL-6 levels were measured via ELISA. Progression-free survival (PFS) and overall survival (OS) were assessed via Kaplan-Meier and Cox regression analyses. We established murine lung adenocarcinoma (LLC) and squamous cell carcinoma (KLN205) models with IL-6 overexpression or inhibition and treated them with anti-PD-1 therapy ± chemotherapy. Tumour growth was monitored, and single-cell RNA sequencing (scRNA-seq) was performed on tumour-infiltrating immune cells. The results showed that patients with high baseline plasma IL-6 levels (>7.002 pg/mL) exhibited significantly worse PFS (median: 7.20 vs. 16.63 months, P = 0.001) and OS (median: 15.63 vs. 32.80 months, P = 0.001) than those with low baseline levels. A high IL-6 level was an independent predictor of worse PFS (HR = 2.42, P < 0.001) and OS (HR = 2.96, P < 0.001) and was correlated with progressive disease (PD, P = 0.018). In murine models, IL-6 overexpression diminished the antitumour efficacy of anti-PD-1 therapy combined with chemotherapy. Moreover, scRNA-seq analysis revealed that IL-6 overexpression skewed macrophage polarisation toward immunosuppressive phenotypes (characterised by Hilpda and Nr4a1 expression) and reduced the proportion of cytotoxic CD8+ T-cells while increasing the proportion of regulatory T-cells (Tregs). Conversely, IL-6 inhibition promoted an immunostimulatory macrophage phenotype (characterised by increased Ccl8 expression) and enhanced CD8+ T-cell infiltration and function. A high IL-6 level was also correlated with impairment of NK cell degranulation pathways. These findings uncovered that an elevated baseline plasma IL-6 level is a robust independent predictor of primary resistance and poor survival in advanced NSCLC patients receiving chemoimmunotherapy. Mechanistically, IL-6 drives formation of an immunosuppressive TIME by promoting protumour macrophage polarisation. This, in turn, suppress cytotoxic T cell infiltration, promoting Treg expansion, and impairing NK cell function, indicating that the targeting of IL-6 represents a promising strategy to overcome resistance to chemoimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Lung NeoplasmsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungMyeloid CellsT-Lymphocytes, CytotoxicHumansAnimalsFemaleMaleMiceTumor MicroenvironmentMiddle AgedRetrospective StudiesImmune Checkpoint InhibitorsAgedAntineoplastic Combined Chemotherapy ProtocolsPrognosisCell Line, TumorLymphocytes, Tumor-InfiltratingImmunotherapy

Stichwörter der Autor:innen

ChemoimmunotherapyIL-6Immunosuppressive tumour microenvironmentNon-small cell lung cancerResistance

Substanzen

Interleukin-6IL6 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Centre d…
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; State Ke…
  • Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.
  • Department of Comprehensive Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Cancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Förderung

  • Fundamental Research Funds for the Central Universities
  • Beijing Xisike Clinical Oncology Research Foundation
  • Youth Science Fund Project
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Y., Liu, C., Yang, L., Zheng, S., Xu, H., Zhang, S., Tian, L., Sun, N., He, J., & Wang, Y. (2026). IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218259

Vancouver

Yang Y, Liu C, Yang L, Zheng S, Xu H, Zhang S, et al. IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218259

BibTeX
@article{Yang2026,
  author = {Yang, Yaning and Liu, Chengming and Yang, Lu and Zheng, Sufei and Xu, Haiyan and Zhang, Shuyang and Tian, Linyan and Sun, Nan and He, Jie and Wang, Yan},
  title = {IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218259}
}
Kostenlos starten →